Protagonist Therapeutics

Historical price data

Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.

Proprietary peptide discovery platform including Vectrix™ molecular design tools, phage display libraries, oral stability assays, and advanced formulation technologies enabling de novo peptide development against diverse biological targets.

14 drugs in pipeline, 2 in Phase 3

Competes with established biologics companies in immunology (AbbVie, Amgen, Novartis) and hematology players (Incyte), but differentiates through oral peptide capabilities and proprietary discovery platform. Head-to-head superiority data for icotrokinra vs. deucravacitinib provides competitive advantage in IL-23 space.